49 results
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
of the applicable performance goals. In addition, POINT may, prior to the Effective Time, amend each these awards to provide that if the holder is terminated … and Current Reports on Form 8-K. In addition, the Projections may be affected by POINT’s ability to achieve strategic goals, objectives and targets over
SC14D9C
EX-99.2
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
5:24pm
committees and activities will continue as planned.
What changes will be made to the current POINT organizational structure or corporate goals?
Integration … planning is in process, and we expect further clarity in the coming weeks. We will continue to be focused on our 2023 corporate goals
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
may not achieve research, development and commercialization goals in the time frames that we publicly estimate. ◦ We may be unable to obtain regulatory … that hope to enhance the safety of actinium-based radioligands, the goals of our tumor microenvironment targeting prodrug platform extend beyond 225Ac
DEF 14A
1j5x6tta
28 Apr 22
Definitive proxy
8:36am
424B3
igc1gcs3jsp2ba08xs
31 Mar 22
Prospectus supplement
11:42am
POS AM
n8cunkbrvumfh ox1
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
EX-10.2
qhak4 spm6n57ynxnx
12 Nov 21
Prospectus supplement
8:41am
424B3
EX-10.4
h7gta4js
12 Nov 21
Prospectus supplement
8:41am
424B3
ik2ak7h6vw 2xkb
5 Aug 21
Prospectus supplement
4:26pm
8-K
EX-10.3
5xq7mpu
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
424B3
uk0zlafkd9 xh62h28
9 Jun 21
Prospectus supplement
4:42pm